Abstract |
Psoriasis is an autoimmune inflammatory disease that has recently been treated with a novel treatment, ustekinumab, a human monoclonal antibody that targets the Th17 pathway. Discoid lupus is a subset of chronic cutaneous lupus erythematosus. Recent studies have suggested the Th17 pathway may be involved in cutaneous lupus. We present a case of a 41-year-old man with both severe psoriasis and hypertrophic discoid lupus treated with ustekinumab. After three doses of 45 mg subcutaneous injections at day 1, week 4, and week 16, his psoriasis plaques cleared and his hypertrophic discoid lupus plaques showed moderate improvement. Following a fourth dose of 90 mg his lupus plaques showed marked improvement. Ustekinumab may be a promising therapy for this and other forms of cutaneous lupus.
|
Authors | D Winchester, K Callis Duffin, C Hansen |
Journal | Lupus
(Lupus)
Vol. 21
Issue 9
Pg. 1007-10
(Aug 2012)
ISSN: 1477-0962 [Electronic] England |
PMID | 22438028
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Ustekinumab
|
Topics |
- Adult
- Antibodies, Monoclonal
(therapeutic use)
- Antibodies, Monoclonal, Humanized
- Humans
- Hypertrophy
- Lupus Erythematosus, Discoid
(drug therapy, pathology)
- Male
- Psoriasis
(drug therapy)
- Th17 Cells
(physiology)
- Ustekinumab
|